SEC Foi	rm 4 FORM	4 U	NITEI	O STAT	ES S	SEC	URITIE	S AN	DE	XCHAN	IGE C	OMI	MISSIC	N			
		Washington, D.C. 20549												OMB APPROVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			STA		IT OF CHANGES IN BENEFICIAL OWNERSHIP pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								RSHIP	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person [*] Gibson Christopher					2. Issuer Name and Ticker or Trading Symbol <u>RECURSION PHARMACEUTICALS</u> , <u>INC.</u> [RXRX]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner y Officer (give title Other (specify				
(Last) C/O REC	(Last) (First) (Middle) C/O RECURSION PHARMACEUTICALS					3. Date of Earliest Transaction (Month/Day/Year) 08/15/2023							X Officer (give the officer (specify below) below) Chief Executive Officer				
41 S. RIO GRANDE STREET (Street) SALT LAKE CITY UT 84101					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)					Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Table	I - No	n-Deriva	tive S	ecur	rities Acq	uired,	Dis	posed of	, or Ber	nefici	ally Ow	ned			
1. Title of Security (Instr. 3) Date (Month/Da				y/Year) if any		Deemed ution Date, / th/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (Disposed Of (D) (Instr. 3 5)			nd Secur Bene Owne	icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price		action(s) 3 and 4)		(Instr. 4)	
Class A Common Stock 08/15/2					2023			F ⁽¹⁾		16,913	D	\$ <mark>9.</mark> :	19 8	73,806	D		
		Ta					ies Acqu varrants,							ed			
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution curity or Exercise (Month/Day/Year) if any		med 4. Transac Code (li Day/Year) 8)			5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		Ownershi Form: Iy Direct (D) or Indirec (I) (Instr. 4	t (Instr. 4)		

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. **Remarks:**

(A)

(D)

Date Exercisable Expiration Date

<u>/s/ Jonathan Golightly,</u>

Title

Amount or Number of Shares

attorney-in-fact

** Signature of Reporting Person Date

08/17/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code V

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.